Daily Stock Analysis, CLSN, Celsion Corp, priceseries

Celsion Corp. Daily Stock Analysis
Stock Information
Open
2.38
Close
2.36
High
2.42
Low
2.33
Previous Close
2.35
Daily Price Gain
0.01
YTD High
2.63
YTD High Date
Mar 12, 2019
YTD Low
1.38
YTD Low Date
Jan 2, 2019
YTD Price Change
0.69
YTD Gain
41.32%
52 Week High
3.48
52 Week High Date
Jun 19, 2018
52 Week Low
1.35
52 Week Low Date
Dec 28, 2018
52 Week Price Change
0.17
52 Week Gain
7.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 14. 2017
1.40
Sep 29. 2017
1.48
11 Trading Days
6.05%
Link
LONG
Oct 6. 2017
3.35
Oct 13. 2017
4.15
5 Trading Days
23.94%
Link
LONG
Nov 20. 2017
2.14
Nov 30. 2017
2.75
7 Trading Days
28.52%
Link
LONG
Mar 2. 2018
2.25
Mar 15. 2018
2.49
9 Trading Days
10.57%
Link
LONG
Jun 14. 2018
2.64
Jun 27. 2018
2.92
9 Trading Days
10.75%
Link
LONG
Jan 14. 2019
1.93
Jan 23. 2019
2.09
6 Trading Days
8.37%
Link
Company Information
Stock Symbol
CLSN
Exchange
NasdaqCM
Company URL
http://www.celsion.com
Company Phone
(609) 896-9100
CEO
Michael H. Tardugno
Headquarters
New Jersey
Business Address
997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ 08648
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000749647
About

Celsion Corp. is an oncology drug development company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA- based therapies. Its products include Celsion, ThermoDox, EGEN, TheraPlas and TheraSilence. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Description

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company also has a collaboration with the Children's Research Institute to conduct a clinical study of ThermoDox, a heat activated liposomal encapsulation of doxorubicin in combination with magnetic resonance-guided high intensity focused ultrasound to treat relapsed or refractory solid tumors in children and young adults. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.